Iron Deficiency Anemia

View All

Pharma News for Pfizer, Daiichi Sankyo, Kyverna, Servier
Daiichi Sankyo’s Intravenous Iron Replacement Therapy; ANeuroTech’s Adjunctive Anti-depression Drug, ANT-01; Kyverna Therapeutics’s KYV-101 in Lupus Nephritis; Servier Presents Data from Phase 3 INDIGO Trial of Vorasidenib; FDA Approves Pfizer’s ABRYSVO

FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults Pfizer Inc. announced that the FDA has authorized ABRYSVO (Respiratory Syncytial Virus Vaccine), the company's bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory...

Find More

iron-deficiency-anemia-market-size-share-trends-companies-cagr-growth-therapy-treatment-therapeutics-pipeline
Iron Deficiency Anemia Market Growth Anticipated to Fuel at a CAGR of 3.7% by 2030

Anemia is a serious cause of global health loss with over 80% of the total cases diagnosed in developing countries, according to several studies. Anemia is characterized by reduced quality of red blood cells, diminished hemoglobin levels and even altered morphology of red blood cells. The symptoms of the condition ...

Find More